Omeros Entered Into Credit And Guaranty Agreement to Provide Senior Secured Term Loan Facility Initially Up To $92.1M

6/3/24 9:05:18 AM ET

$OMER

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $OMER alert in real time by email

$118.1 million, or 55%, of outstanding convertible notes due in 2026 repurchased at approximately 75% of notional value, resulting in $51 million in total debt extinguishment
Repurchase funded from new $67 million secured four-year term loan maturing in June 2028 together with $21 million cash on hand
Credit facility includes $25 million delayed draw term loan conditionally available to fund narsoplimab commercialization
Transactions include no equity component, preventing shareholder dilution, and enable additional debt reduction

Get the next $OMER alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$OMER

Date	Price Target	Rating	Analyst
11/14/2024	$9.00	Buy	Rodman & Renshaw
12/8/2022	$12.00 → $2.00	Buy → Neutral	UBS
11/8/2022	$8.00 → $3.00	Neutral → Underperform	BofA Securities
6/8/2022	$12.00 → $4.00	Buy → Neutral	BofA Securities
10/19/2021	$19.00 → $12.00	Buy	HC Wainwright & Co.
10/8/2021		Neutral → Underweight	JP Morgan
10/6/2021	$32.00 → $19.00	Buy	HC Wainwright & Co.
10/4/2021		Buy → Hold	Maxim Group

More analyst ratings

$OMER
Financials

Live finance-specific insights

Omeros Corporation Reports Third Quarter 2024 Financial Results
– Conference Call Today at 4:30 p.m. ET Omeros Corporation (NASDAQ:OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2024, which include: Net loss for the third quarter of 2024 was $32.2 million, or $0.56 per share, compared to a net loss of $37.8 million, or $0.60 per share for the third quarter of 2023. For the nine months ended September 30, 2024, net loss was $125.5 million, or $2.15 per share, compared to a net loss of $108.8 million, or $1.73 per share in the prior year period. At September 30, 2024, we had $123.2 million of cash and short-term investments available for operations and debt servicing,
11/13/24 4:02:00 PM ET
$OMER
Biotechnology: Pharmaceutical Preparations
Health Care
Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024
Omeros Corporation (NASDAQ:OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2024, on Wednesday, November 13, 2024, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details For online access to the live webcast of the conference call, go to Omeros' website at https://investor.omeros.com/upcoming-events. To access the live conference call via phone, participants must register at this link to receive a unique PIN. Once registered, you wi
11/11/24 4:11:00 PM ET
$OMER
Biotechnology: Pharmaceutical Preparations
Health Care
Omeros Corporation Reports Second Quarter 2024 Financial Results
– Conference Call Today at 4:30 p.m. ET Omeros Corporation (NASDAQ:OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, as well as cancers and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2024, which include: Net loss for the second quarter of 2024 was $56.0 million, or $0.97 per share, compared to a net loss of $37.3 million, or $0.59 per share for the second quarter of 2023.
8/7/24 4:02:00 PM ET
$OMER
Biotechnology: Pharmaceutical Preparations
Health Care

Omeros Corporation Provides Update on Progress Toward BLA Resubmission
Omeros Corporation (NASDAQ:OMER) today announced an update on its progress toward planned resubmission of its biologics license application ("BLA") for narsoplimab, the company's first-in-class antibody targeting MASP-2, the effector enzyme of the lectin pathway of complement, in hematopoietic stem cell transplant-associated thrombotic microangiopathy ("TA-TMA"). In last week's quarterly earnings release and associated call, Omeros stated that it was awaiting feedback from the U.S. Food and Drug Administration ("FDA") on the company's revised statistical analysis plan ("SAP") for the BLA. Omeros has now received FDA's response on the revised SAP, has no other presubmission information reque
11/21/24 9:15:00 AM ET
$OMER
Biotechnology: Pharmaceutical Preparations
Health Care
Omeros Corporation Reports Third Quarter 2024 Financial Results
– Conference Call Today at 4:30 p.m. ET Omeros Corporation (NASDAQ:OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2024, which include: Net loss for the third quarter of 2024 was $32.2 million, or $0.56 per share, compared to a net loss of $37.8 million, or $0.60 per share for the third quarter of 2023. For the nine months ended September 30, 2024, net loss was $125.5 million, or $2.15 per share, compared to a net loss of $108.8 million, or $1.73 per share in the prior year period. At September 30, 2024, we had $123.2 million of cash and short-term investments available for operations and debt servicing,
11/13/24 4:02:00 PM ET
$OMER
Biotechnology: Pharmaceutical Preparations
Health Care
Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024
Omeros Corporation (NASDAQ:OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2024, on Wednesday, November 13, 2024, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details For online access to the live webcast of the conference call, go to Omeros' website at https://investor.omeros.com/upcoming-events. To access the live conference call via phone, participants must register at this link to receive a unique PIN. Once registered, you wi
11/11/24 4:11:00 PM ET
$OMER
Biotechnology: Pharmaceutical Preparations
Health Care

Omeros Entered Into Credit And Guaranty Agreement to Provide Senior Secured Term Loan Facility Initially Up To $92.1M

Chat with this insight

Recent Analyst Ratings for $OMER

$OMER Financials

Live finance-specific insights

Omeros Corporation Reports Third Quarter 2024 Financial Results

Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024

Omeros Corporation Reports Second Quarter 2024 Financial Results

$OMER SEC Filings

$OMER Leadership Updates

Live Leadership Updates

$OMER Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$OMER Press Releases

Fastest customizable press release news feed in the world

SEC Form 10-Q filed by Omeros Corporation

Omeros Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by Omeros Corporation

Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer

Rodman & Renshaw initiated coverage on Omeros with a new price target

Omeros downgraded by UBS with a new price target

Omeros downgraded by BofA Securities with a new price target

Omeros Corporation Provides Update on Progress Toward BLA Resubmission

Omeros Corporation Reports Third Quarter 2024 Financial Results

Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024

$OMER Market Insights

Live Market Insights

Needham Reiterates Hold on Omeros

Omeros Entered Into Credit And Guaranty Agreement to Provide Senior Secured Term Loan Facility Initially Up To $92.1M

Crude Oil Moves Higher; Deere Cuts Profit Outlook

$OMER Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

New insider Borges David J. claimed ownership of 30,000 shares (SEC Form 3)

SEC Form 4 filed by Shah Rajiv

SEC Form 4 filed by Perkinson Diana T.

$OMER Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Demopulos Gregory A Md bought $25,200 worth of shares (15,000 units at $1.68) (SEC Form 4)

Demopulos Peter A Md bought $15,300 worth of shares (10,000 units at $1.53), increasing direct ownership by 5% to 208,516 units (SEC Form 4)

$OMER Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Omeros Corporation (Amendment)

SEC Form SC 13G/A filed by Omeros Corporation (Amendment)

SEC Form SC 13G filed by Omeros Corporation

Recent Analyst Ratings for
$OMER

$OMER
Financials

$OMER
SEC Filings

$OMER
Leadership Updates

$OMER
Analyst Ratings

$OMER
Press Releases

$OMER
Market Insights

$OMER
Insider Trading

$OMER
Insider Purchases

$OMER
Large Ownership Changes